摘要
新型冠状病毒肺炎(COVID-19)仍在全球范围内传播,尚无特效药应用于临床。乌司他丁(ulinastatin)在抗炎方面发挥重要作用,临床上主要应用于急性胰腺炎、休克和弥散性血管内凝血等,其还具有抗氧化应激、抗凝、免疫调节作用,可能对于降低COVID-19的严重程度和死亡率有重要意义。主要结合乌司他丁的药理作用及其在治疗急性呼吸窘迫综合征、脓毒症肺损伤等COVID-19并发症中的临床应用,论述其应用于COVID-19的可行性,以期为该病的临床治疗及新药研发提供帮助。
Coronavirus disease 2019(COVID-19)is still spreading worldwide.At present,no specific drug has been developed for the virus.Ulinastatin plays an important role in anti-inflammatory.Clinically,it is mainly used in acute pancreatitis,shock and disseminated intravascular coagulation.It also has the effects of antioxidant stress,anticoagulation and immune regulation,which may be of great significance to reduce the severity and mortality of COVID-19.Combined with the pharmacological effect of ulinastatin and its clinical application in the treatment of COVID-19 complications such as acute respiratory distress syndrome and sepsis lung injury,this paper discusses the feasibility of its application in COVID-19,so as to provide help for the clinical treatment and new drug research and development of this disease.
作者
李彦静
孙美艳
李星月
王春玲
孙银贵
赵虹翔
赵晓勇
LI Yanjing;SUN Meiyan;LI Xingyue;WANG Chunling;SUN Yingui;ZHAO Hongxiang;ZHAO Xiaoyong(Department of Anesthesiology,Affiliated Hospital of Weifang Medical College,Weifang 261021,China;Shandong Provincial Medicine and Health Key Laboratory of Clinical Anesthesia,School of Anesthesiology,Weifang Medical University,Weifang 261021,China;Department of Hepatobiliary and Pancreatic Surgery,Affiliated Hospital of Weifang Medical College,Weifang 261021,China)
出处
《药物评价研究》
CAS
2022年第1期186-192,共7页
Drug Evaluation Research
基金
山东省医药卫生科技发展计划项目(2019WS605,202104110334,202104110339,202104010549)
潍坊市科技发展计划项目(2021YX028)
潍坊医学院大学生创新创业培训项目(X2021523,X2021516)。
关键词
乌司他丁
新型冠状病毒肺炎
急性呼吸窘迫综合征
脓毒症肺损伤
ulinastatin
coronavirus disease 2019(COVID-19)
acute respiratory distress syndrome
sepsis lung injury
